HCP
Dymista Menu
HCP
 

Dymista®: Twice as effective as fluticasone propionate and azelastine hydrochloride in providing relief from nasal congestion 

Dymista®: Three times as effective as fluticasone propionate and azelastine hydrochloride in providing relief from ocular itching 

Dymista®: superior in providing faster and substantial relief compared to FP & AZE, defined as ≥ 50% reduction in nasal symptoms

Dymista®: Impact of treatment by disease severity  

left left
right right
Dymista®: Twice as effective as fluticasone propionate and azelastine hydrochloride in providing relief from nasal congestion 
Dymista®: Three times as effective as fluticasone propionate and azelastine hydrochloride in providing relief from ocular itching 
Dymista®: superior in providing faster and substantial relief compared to FP & AZE, defined as ≥ 50% reduction in nasal symptoms
Dymista®: Impact of treatment by disease severity  

† p=0.0034 vs.  Dymista®

FP: fluticasone propionate

Adapted from Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

In a double-blind, placebo-controlled, 14 day, parallel-group trial, 610 patients (≥12 years old) with moderate-to-severe SAR were randomised to either Dymista®, commercially-available azelastine (AZE) or fluticasone propionate (FP) nasal sprays and placebo (all given as 1 spray/nostril bid (total daily doses: AZE = 548µg: FP = 200µg) Adapted from Price et al. A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex.Clinical and Translational Allergy 2013; 3 (2): 45.

rT7SS: Total of 7 symptom scores (All nasal plus all ocular symptoms); FP: fluticasone propionate (n=151) AZE: azelastine (n=152); Dymista® (n= 153). Results expressed as LS mean change from baseline (delta placebo) with 95% CI.  

 

Problem: Patients with allergic rhinitis suffer from both nasal and ocular symptoms.

Solution: Dymista® is a major advancement in the treatment of allergic rhinitis since it is twice as effective as an intranasal corticosteroid (fluticasone propionate) or antihistamine (azelastine), providing relief from both nasal and ocular symptoms.

*Dymista®

 

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

† p=0.0001 vs.  Dymista®

FP: fluticasone propionate

Adapted from Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

In a double-blind, placebo-controlled, 14 day, parallel-group trial, 610 patients (≥12 years old) with moderate-to-severe SAR were randomised to either Dymista®, commercially-available azelastine (AZE) or fluticasone propionate (FP) nasal sprays and placebo (all given as 1 spray/nostril bid (total daily doses: AZE = 548µg: FP = 200µg) Adapted from Price et al. A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex. Clinical and Translational Allergy 2013; 3 (2): 45.

rT7SS: Total of 7 symptom scores (All nasal plus all ocular symptoms); FP: fluticasone propionate (n=151) AZE: azelastine (n=152); Dymista® (n= 153). Results expressed as LS mean change from baseline (delta placebo) with 95% CI.  

 

Problem: Patients with allergic rhinitis suffer from both nasal and ocular symptoms.

Solution: Dymista® is a major advancement in the treatment of allergic rhinitis since it is twice as effective as an intranasal corticosteroid (fluticasone propionate) or antihistamine (azelastine), providing relief from both nasal and ocular symptoms.

*Dymista®

 

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Adapted from Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02*) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

FP: fluticasone propionate; AZE: azelastine; PLA: placebo; AR: allergic rhinitis Responder rate = % of patients with a 50% or more reduction in Total Nasal Symptom Score.

The total daily doses of AZE and FP were 548 µg and 200 µg, respectively.

FP: fluticasone propionate (n=152) AZE: azelastine (n=151) Dymista® (n= 153) PLA: placebo (n=151)

Problem: Many allergic rhinitis patients do not adhere to their treatment regimen as substantial symptom relief is not achieved quickly enough.

Solution: Dymista® patients achieve substantial control of their nasal symptoms and do so up to 6 days faster than those on fluticasone propionate.

*Dymista®

Adapted from Meltzer et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161:369-77.

AR: allergic rhinitis; FP: fluticasone propionate; AZE: azelastine; rTNSS: reflective Total Nasal Symptom Score. Results expressed as LS mean change from baseline (delta placebo) with 95% CI.

 

Problem: Most patients presenting with allergic rhinitis have moderate-to-severe symptoms. 

Solution: Dymista® provides benefits for all patients regardless of the severity of their symptoms. Allergic rhinitis patients treated with Dymista® experience significantly greater overall relief from their nasal symptoms than either intranasal fluticasone propionate or azelastine hydrochloride,  even those with more severe symptoms who are currently difficult to treat.

*Dymista®

UK/DYM/14/0070(1) Date of Prep: February 2017

Login

Log in

CloseClose

Sign in to Dymista

Don't have a Dymista account?

The website you are trying to access is designed for UK Healthcare Professionals only - the content is not designed for the general public.


Are you a UK Healthcare Professional?

Yes No
Why do I need to answer this?

No, I am not a HCP

Sorry, you do not have the authorization to enter this webpage.

Go back Go back
close-icon